InsidersTradesSigma
Total declarations
Companies
▲ Purchases (22 ops.)
▼ Sales (2 ops.)
Discover the full record of transactions filed by Cormorant Asset Management, LP. Officer active across 10 companies, notably Verve Therapeutics, Inc.. In total, 66 filings have been logged. Total volume traded: €76.7m. The latest transaction was filed on 12 May 2026 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations66 total
€135,5186,387 shares@ €21.217850.0% of flow
Common Stock
SEC:0001231919-26-000495:0·
Ideal exit: 6 Feb 2027 (T+270)
€135,5186,387 shares@ €21.2178100.0% of flow
Common Stock
SEC:0001231919-26-000495·
Ideal exit: 6 Feb 2027 (T+270)
€2,291302 shares@ €7.58590.0014% mcap1.5% of flow
Common Stock
SEC:0001104659-22-073920:0·
Ideal exit: 18 Mar 2023 (T+270)
€19m9,480,052 shares@ €2.03850.61% mcap100.0% of flow
Ordinary Shares
SEC:0001104659-22-072990:0·
Ideal exit: 13 Mar 2023 (T+270)
€151,70220,000 shares@ €7.58510.094% mcap98.5% of flow
Common Stock
SEC:0001104659-22-071465:0·
Ideal exit: 10 Mar 2023 (T+270)
05,543 shares0
Common Stock
SEC:0001104659-22-071026:0·
04,500 shares0
Common Stock
SEC:0001104659-22-069745:0·
€340,6961,005,686 shares@ €0.33882.20% mcap30.9% of flow
Common Stock
SEC:0001104659-22-065351:0·
€760,6221,250,000 shares@ €0.60854.91% mcap69.1% of flow
Common Stock
SEC:0001104659-22-064706:0·
3,642,229 shares
Common Stock
SEC:0001104659-22-059645:0·
€31m2,200,000 shares@ €14.09316.41% mcap100.0% of flow
Common Stock
SEC:0001104659-22-052318:0·
Ideal exit: 21 Jan 2023 (T+270)
1,699,998 shares
Common Stock
SEC:0001104659-22-041080:0·
€722,778175,318 shares@ €4.1227100.0% of flow
Common Stock
SEC:0001104659-22-040146:0·
Ideal exit: 23 Dec 2022 (T+270)
€4m342,143 shares@ €11.29290.88% mcap32.1% of flow
Common Stock
SEC:0001104659-22-034568:0·
Ideal exit: 9 Dec 2022 (T+270)
€478,75040,154 shares@ €11.92290.11% mcap4.0% of flow
Common Stock
SEC:0001104659-22-032990:0·
Ideal exit: 4 Dec 2022 (T+270)
€747,48563,662 shares@ €11.74150.17% mcap6.2% of flow
Common Stock
SEC:0001104659-22-031596:0·
Ideal exit: 29 Nov 2022 (T+270)
€101,4498,746 shares@ €11.59940.023% mcap0.8% of flow
Common Stock
SEC:0001104659-22-029417:0·
Ideal exit: 25 Nov 2022 (T+270)
€3m214,922 shares@ €11.84090.58% mcap21.1% of flow
Common Stock
SEC:0001104659-22-027432:0·
Ideal exit: 20 Nov 2022 (T+270)
€2m166,229 shares@ €12.99520.49% mcap17.9% of flow
Common Stock
SEC:0001104659-22-025736:0·
Ideal exit: 14 Nov 2022 (T+270)
€2m166,229 shares@ €12.95220.49% mcap17.9% of flow
Common Stock
SEC:0001104659-22-024375:0·
Ideal exit: 11 Nov 2022 (T+270)
616,786 shares
Common Stock
SEC:0001567619-22-001163·
616,786 shares
Common Stock
SEC:0001567619-22-001163:0·
785,303 shares
Common Stock
SEC:0001567619-21-018789·
785,303 shares
Common Stock
SEC:0001567619-21-018789:0·
668,854 shares
Common Stock
SEC:0001567619-21-018355·
25 of 66 declarations
About Cormorant Asset Management, LP
Cormorant Asset Management, LP is a significant shareholder of Verve Therapeutics, Inc.
